TriHealth Partners with RevealDx to Study AI’s Impact on Lung Nodule Assessment

What You Should Know: 

– TriHealth, a nationally recognized healthcare system based in Cincinnati, Ohio, announced a new partnership with RevealDx, a company specializing in Medical Imaging Artificial Intelligence (AI). 

– The collaboration aims to bring greater precision and personalization to the diagnosis and management of lung nodules through a clinical study evaluating RevealDx’s AI technology.

The Challenge of Assessing Lung Nodules

Lung nodules are relatively common findings on medical imaging scans. While the majority are benign, a small percentage can represent early-stage lung cancer, making timely and accurate assessment critical. Dr. Doug Adams of TriHealth noted the traditional approach often involves detection, measurement, and repeated scanning, which can potentially delay the diagnosis of lung cancer.

TriHealth’s Advanced Lung Nodule Program

TriHealth has already established itself as a leader in lung nodule management. The health system utilizes advanced techniques like robotic bronchoscopy for faster, more accurate tissue sampling with quicker patient recovery. Furthermore, TriHealth has previously integrated sophisticated software tools into its workflow, including Riverain Technologies’ AI software to enhance nodule detection on CT scans and Thynk Health’s software to streamline the identification, management, and outcome analysis of lung nodules.

“For decades, lung nodule assessment has followed a pattern of detection, measurement, and repeated scanning—often resulting in delayed diagnosis of lung cancer,” said Dr. Adams. “AI tools now offer the potential to deliver critical insights at the very first scan. When paired with AI-driven informatics, this represents a significant step forward. We’re eager to study how these tools improve care in a real-world setting.”